12 Month Price Forecast For MEDP
Distance to MEDP Price Forecasts
MEDP Price Momentum
🤔 Considering Medpace (MEDP)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 10:13 AM UTC
MEDP Analyst Ratings & Price Targets
Based on our analysis of 14 Wall Street analysts, MEDP has a consensus that is neutral. The median price target is $348.50, with forecasts ranging from $296.00 to $400.00. Currently, there are 4 Buy ratings, 6 Hold ratings, and 1 Sell ratings.
With MEDP currently trading at $345.18, the median price forecast suggests a 1.0% upside. The most optimistic forecast comes from at , projecting a 15.9% upside, while at provides the most conservative target, suggesting a -14.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MEDP Analyst Consensus
MEDP Price Target Range
Latest MEDP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MEDP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 25, 2024 | Baird | Eric Coldwell | Neutral | Maintains | $354.00 |
| Oct 23, 2024 | Baird | Eric Coldwell | Neutral | Downgrade | $349.00 |
| Oct 23, 2024 | TD Cowen | Charles Rhyee | Buy | Maintains | $372.00 |
| Oct 22, 2024 | William Blair | Max Smock | Outperform | Reiterates | $0.00 |
| Oct 14, 2024 | Truist Securities | Jailendra Singh | Hold | Maintains | $397.00 |
| Oct 14, 2024 | Redburn Atlantic | Buy | Initiates | $404.00 | |
| Sep 27, 2024 | UBS | Dan Leonard | Neutral | Downgrade | $350.00 |
| Sep 25, 2024 | Jefferies | David Windley | Hold | Downgrade | $345.00 |
| Sep 20, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $413.00 |
| Sep 11, 2024 | William Blair | Max Smock | Outperform | Reiterates | $0.00 |
| Aug 1, 2024 | Truist Securities | Jailendra Singh | Hold | Initiates | $415.00 |
| Jul 24, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $430.00 |
| Jul 24, 2024 | Deutsche Bank | Justin Bowers | Hold | Maintains | $336.00 |
| Jul 24, 2024 | Guggenheim | Sandy Draper | Buy | Maintains | $432.00 |
| Jul 24, 2024 | TD Cowen | Charles Rhyee | Buy | Maintains | $434.00 |
| Jul 23, 2024 | William Blair | Max Smock | Outperform | Reiterates | $0.00 |
| Jul 8, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $469.00 |
| May 29, 2024 | TD Cowen | Charles Rhyee | Buy | Initiates | $452.00 |
| May 28, 2024 | Mizuho | Ann Hynes | Buy | Initiates | $435.00 |
| Apr 24, 2024 | Baird | Eric Coldwell | Outperform | Maintains | $454.00 |
Stocks Similar to Medpace Holdings Inc
The following stocks are similar to Medpace based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medpace Holdings Inc (MEDP) Financial Data
Medpace Holdings Inc has a market capitalization of $10.80B with a P/E ratio of 30.4x. The company generates $2.07B in trailing twelve-month revenue with a 17.7% profit margin.
Revenue growth is +8.3% quarter-over-quarter, while maintaining an operating margin of +21.1% and return on equity of +54.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Medpace Holdings Inc (MEDP) Company Overview
About Medpace Holdings Inc
Provides clinical research and development services.
The company operates by offering a comprehensive range of clinical development services to pharmaceutical, biotechnology, and medical device companies. It generates revenue through the provision of specialized services that support each phase of the clinical development process, from planning and regulatory compliance to monitoring and data analysis.
Founded in 1992 and headquartered in Cincinnati, Ohio, the company serves clients across North America, Europe, and Asia, and focuses on various therapeutic areas. Its diverse offerings include bio-analytical laboratory services and clinical trial support, positioning it as a key player in the clinical research industry.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
5,900
CEO
Dr. August James Troendle M.D.
Country
United States
IPO Year
2016
Website
www.medpace.comMedpace Holdings Inc (MEDP) Latest News & Analysis
The Schall Law Firm is investigating Medpace Holdings, Inc. (NASDAQ:MEDP) for potential securities law violations regarding misleading statements to investors.
The investigation into Medpace for potential securities law violations could indicate risks of stock price volatility, affecting investor confidence and potential financial losses.
The Schall Law Firm is investigating Medpace Holdings, Inc. (NASDAQ:MEDP) for potential securities law violations related to misleading statements affecting investors.
The investigation into Medpace Holdings for potential securities law violations could lead to legal ramifications, impacting stock prices and investor confidence in the company.
The Schall Law Firm is investigating Medpace Holdings, Inc. (NASDAQ:MEDP) for potential securities law violations, including false statements and undisclosed information affecting investors.
The investigation into Medpace for potential securities law violations could lead to legal challenges, impacting stock performance and investor confidence.
Medpace (MEDP) closed at $352.01, up 0.32% from the previous trading session.
Medpace's modest gain indicates market confidence and stability in its stock, which can influence investor sentiment and potential future investment decisions.
The Schall Law Firm is investigating Medpace Holdings, Inc. for potential securities law violations, including possible misleading statements to investors.
The investigation into Medpace for potential securities law violations could signal regulatory risks, impacting stock performance and investor confidence in the company.
Five stocks with increasing P/E ratios are highlighted: Constellation Brands, Edgewell Personal Care, Rent the Runway, Medpace, and Canoo.
Rising P/E ratios may indicate growth potential or investor optimism about future earnings, suggesting these stocks could outperform the market or signal changing investor sentiment.
Frequently Asked Questions About MEDP Stock
What is Medpace Holdings Inc's (MEDP) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Medpace Holdings Inc (MEDP) has a median price target of $348.50. The highest price target is $400.00 and the lowest is $296.00.
Is MEDP stock a good investment in 2025?
According to current analyst ratings, MEDP has 4 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $345.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MEDP stock?
Wall Street analysts predict MEDP stock could reach $348.50 in the next 12 months. This represents a 1.0% increase from the current price of $345.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Medpace Holdings Inc's business model?
The company operates by offering a comprehensive range of clinical development services to pharmaceutical, biotechnology, and medical device companies. It generates revenue through the provision of specialized services that support each phase of the clinical development process, from planning and regulatory compliance to monitoring and data analysis.
What is the highest forecasted price for MEDP Medpace Holdings Inc?
The highest price target for MEDP is $400.00 from at , which represents a 15.9% increase from the current price of $345.18.
What is the lowest forecasted price for MEDP Medpace Holdings Inc?
The lowest price target for MEDP is $296.00 from at , which represents a -14.2% decrease from the current price of $345.18.
What is the overall MEDP consensus from analysts for Medpace Holdings Inc?
The overall analyst consensus for MEDP is neutral. Out of 14 Wall Street analysts, 4 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $348.50.
How accurate are MEDP stock price projections?
Stock price projections, including those for Medpace Holdings Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
